HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
11.45
+0.22 (1.96%)
May 29, 2026, 4:00 PM EDT - Market closed
HUTCHMED (China) Employees
HUTCHMED (China) had 1,796 employees as of December 31, 2025. The number of employees decreased by 15 or -0.83% compared to the previous year.
Employees
1,796
Change (1Y)
-15
Growth (1Y)
-0.83%
Revenue / Employee
$305,408
Profits / Employee
$254,404
Market Cap
2.03B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,796 | -15 | -0.83% |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Evotec SE | 4,526 |
| Phibro Animal Health | 2,475 |
| ANI Pharmaceuticals | 970 |
| Prestige Consumer Healthcare | 890 |
| Supernus Pharmaceuticals | 778 |
| BioCryst Pharmaceuticals | 435 |
HCM News
- 1 day ago - A Look at HUTCHMED (China) Ltd (HCM) After 4.3% Decline -- GF Value $13.82 vs Price $11.22 - GuruFocus
- 1 day ago - Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley - TheFly
- 8 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 9 days ago - Hutchmed And Innovent Secure NMPA Approval For ELUNATE-TYVYT Combo In Advanced Renal Cell Carcinoma - Nasdaq
- 9 days ago - HCM Receives Approval for New Cancer Treatment in China - GuruFocus
- 9 days ago - Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination - TheFly
- 9 days ago - Hutchmed, Innovent Biologics announce China NMPA approval for NDA - TheFly
- 9 days ago - HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma - GlobeNewsWire